Replies to post #248690 on Biotech Values

[DewDiligence]

HRMY—(-30%)—misses primary endpoint_in phase-3 idiopathic hypersomnia trial:

https://finance.yahoo.com/news/harmony-biosciences-announces-topline-data-120000326.html

A positive trend favoring pitolisant was observed during the 4-week double-blind randomized withdrawal period, however no statistically significant difference was observed between pitolisant and placebo groups on ESS, the primary endpoint.